| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1f2e4e429bc5ffc6349323ddbd70948
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e803ac0da498bbf8a94b16ec9882440
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0850e6d391dbbbf587a8a5a3cf1ab962
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60c88bf15cecac871900ae238a190126
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88ca357e518938bf8822df67e80acf2c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate |
2005-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6d8f2096ab5d3e8e5b464e6ebbe35b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85a0446b1eb01f63684cbf2a43085150
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb1ec0683ef7794a39326962b06b89e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02947ae7bdbf7893e80e4100a34595d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30050925e281742fb34ed2bd7c3e3792 |
| publicationDate |
2013-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8378109-B2 |
| titleOfInvention |
Labeled ALPHA4BETA2 ligands and methods therefor |
| abstract |
Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with α4ββ2 dysfunction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014050663-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9029557-B2 |
| priorityDate |
2004-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |